Endometrial Cancer

Endometrial cancer is a malignancy of the uterine lining (endometrium) and represents the most common gynecologic malignancy in developed countries, with an incidence of approximately 50,000 new cases annually in the United States. The disease primarily affects postmenopausal women, with a median age of diagnosis around 63 years, and has shown increasing incidence correlating with rising obesity rates. Two distinct pathophysiologic subtypes exist: Type I (estrogen-dependent, ~80% of cases) with generally favorable prognosis, and Type II (estrogen-independent, ~10-20% of cases) with aggressive behavior and poor outcomes. Early detection through awareness of abnormal vaginal bleeding permits diagnosis at earlier stages when prognosis is excellent, making this disease critically important for primary care providers and specialists. Understanding endometrial cancer pathophysiology and management is essential for USMLE Step 2 CK examination success given its high prevalence and frequent clinical presentation in practice.

The pathophysiology of endometrial cancer is fundamentally organized into two molecular and clinical paradigms that drive distinct disease presentations and outcomes:

Type I endometrial cancers (primarily endometrioid histology, ~70% of all endometrial cancers) arise through prolonged unopposed estrogen exposure acting on endometrial tissue lacking progesterone-mediated protective effects. Estrogen drives proliferation of endometrial glandular epithelium through estrogen receptor (ER) signaling, which activates growth-promoting pathways including MAPK/ERK and PI3K/AKT cascades. This chronic proliferative stimulus creates a precancerous state termed atypical endometrial hyperplasia (AEH), characterized by complex glandular architecture, cytologic atypia, and loss of normal maturation. The progression from hyperplasia to carcinoma involves successive genetic alterations, particularly PTEN loss (loss of phosphatase and tensin homolog), which eliminates a critical negative regulator of PI3K/AKT signaling and occurs in ~30% of endometrial cancers and precursor lesions. Additional frequent molecular alterations include KRAS mutations (~30% of Type I cancers), PIK3CA mutations (~15-20%), TP53 mutations (less common in Type I, ~10%), and microsatellite instability (MSI) from mismatch repair gene defects (~30%). These mutations cumulatively drive unrestricted cellular proliferation, evasion of apoptosis, and genomic instability. The clinical manifestation of increased endometrial cell proliferation is abnormal vaginal bleeding as dysplastic endometrial tissue erodes overlying endometrium and exposes friable, hyperplastic mucosa. Type I cancers are typically lower-grade (Grade 1-2), often confined to the uterus at diagnosis, and demonstrate relatively favorable prognosis (~85% 5-year survival) because they are detected earlier through obvious symptoms and grow more slowly.

Type II endometrial cancers (primarily serous and clear cell histologies, ~10-20% of cases) develop independently of estrogen stimulation through aggressive molecular pathways characterized by early TP53 mutations. These mutations inactivate the p53 tumor suppressor protein, eliminating critical checkpoints for DNA damage response and apoptosis; TP53 mutations are detected in 50-90% of Type II cancers compared to only 10-15% of Type I tumors. Type II cancers frequently harbor additional alterations including PTEN loss, HER2 amplification (~20-30% of serous cancers), and elevated microsatellite instability. These mutations drive rapid cell cycle progression through loss of G1/S checkpoint control and diminished apoptosis in response to cellular stress. Type II cancers arise from a precursor lesion called endometrial intraepithelial carcinoma (EIC), which may develop in atrophic endometrium without prior hyperplasia—explaining why these cancers can emerge without the antecedent abnormal bleeding that characterizes Type I disease. The aggressive molecular profile of Type II cancers correlates with deep myometrial invasion, lymphovascular space invasion (LVSI), and early extrauterine spread; these tumors demonstrate poor prognosis (~50% 5-year survival) with frequent recurrence even after comprehensive surgical staging. Importantly, Type II cancers are resistant to progestin therapy, which explains the differential treatment approaches between the two subtypes.

The sustained estrogen excess driving Type I endometrial cancer operates through multiple tissue-level mechanisms. Peripheral aromatization in adipose tissue contributes excess estrogen, particularly relevant to the obesity-endometrial cancer association; obese women have higher circulating and tissue estrogen levels due to increased aromatase expression in expanded adipose compartments. Additionally, increased local aromatase expression occurs within hyperplastic and malignant endometrial tissue itself, creating a feedforward mechanism of increasing local estrogen production. Insulin resistance and hyperinsulinemia (common comorbidities in obese women) directly stimulate ovarian androgen production and inhibit hepatic synthesis of sex hormone-binding globulin (SHBG), further elevating free estrogen levels. The loss of progesterone receptor (PR) expression in many endometrial cancers represents a critical checkpoint failure; even in the presence of adequate progesterone, malignant cells lacking PR cannot respond to the antiproliferative, pro-differentiating effects of progesterone signaling. This explains why some women with adequate progesterone levels still develop cancer—the cancer cells have lost receptors necessary for response. The cumulative result is unopposed estrogen-driven proliferation that overwhelms normal cellular regulatory mechanisms.

Contemporary molecular classification schemes, including the Cancer Genome Atlas (TCGA) categorization, subdivide endometrial cancers into four groups based on genetic features with prognostic significance: (1) POLE-mutant tumors (ultramutated, favorable prognosis despite high-grade histology), (2) mismatch repair-deficient/microsatellite unstable (MMR-d/MSI) tumors (intermediate risk, responsive to immunotherapy), (3) TP53-mutant tumors (copy-number high, aggressive, poor prognosis), and (4) CTNNB1-mutant/no specific molecular features (copy-number low, intermediate prognosis). These molecular features increasingly drive treatment decisions, particularly regarding adjuvant therapy escalation and immunotherapy eligibility, and represent emerging areas of USMLE emphasis.

Unopposed estrogen represents the central etiologic principle for Type I endometrial cancer development and encompasses multiple clinical scenarios. Obesity is the single strongest modifiable risk factor, with relative risk increasing 2-3 fold in obese women (BMI ≥30) due to increased peripheral aromatization; this association explains much of the rising endometrial cancer incidence in developed nations. Estrogen-producing ovarian pathology, particularly polycystic ovary syndrome (PCOS), predisposes to endometrial cancer through chronic anovulation, unopposed estrogen secretion, and associated insulin resistance. Tamoxifen therapy for breast cancer creates unopposed estrogenic effects on endometrial tissue despite its antagonistic effects on breast tissue, increasing endometrial cancer risk 2-3 fold during treatment; this necessitates surveillance in women receiving tamoxifen. Exogenous estrogen replacement therapy (ERT) without concurrent progestin in postmenopausal women increases endometrial cancer risk 2-10 fold depending on dose, duration, and endometrial thickness; combined estrogen-progestin therapy eliminates this excess risk, and absolute risk increases with duration beyond 5 years of use.

Type 2 diabetes mellitus is independently associated with increased endometrial cancer risk (relative risk 1.5-2.5 fold), operating through multiple mechanisms beyond obesity alone. Chronic hyperinsulinemia stimulates ovarian theca cell androgen production and suppresses hepatic SHBG synthesis, both elevating free estrogen availability. Insulin-like growth factor-1 (IGF-1) signaling, enhanced in insulin-resistant states, directly stimulates endometrial cell proliferation through tyrosine kinase activation and PI3K/AKT pathway engagement. Metabolic dysfunction increases systemic inflammation with elevated circulating interleukin-6 and TNF-α, which promote additional aromatase expression and proliferative signaling in endometrial tissue.

Advancing age represents a non-modifiable risk factor, with median age at diagnosis approximately 63 years and incidence rising sharply after age 50. Postmenopausal status (typically age >50) increases risk due to prolonged cumulative estrogen exposure without the protective effects of monthly progesterone surges during the luteal phase that occur in reproductive-aged women. However, the distinction that abnormal bleeding in postmenopausal women should never be attributed to menopause itself is critical—all postmenopausal bleeding represents endometrial cancer until proven otherwise through appropriate investigation.

Lynch syndrome (hereditary non-polyposis colorectal cancer or HNPCC), caused by germline mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2), confers a 40-60% lifetime risk of endometrial cancer, making it the second most common Lynch syndrome-associated malignancy. Lynch syndrome endometrial cancers often develop at younger ages (mean age ~50 years) and may be diagnosed incidentally during colorectal cancer surveillance or present with earlier-stage disease if detected through awareness of family history. Cowden syndrome (PTEN-associated cancer predisposition) increases endometrial cancer risk through germline PTEN inactivation. BRCA1/BRCA2 mutations are associated with modestly increased endometrial cancer risk (relative risk 1.5-2 fold), though breast and ovarian cancers dominate the cancer spectrum in these syndromes.

Postmenopausal bleeding (PMB) is the classic and most common presenting symptom, occurring in 90% of early-stage endometrial cancers and demands thorough investigation in all cases. Mechanistically, abnormal bleeding results from erosion of friable, hyperplastic endometrial tissue with increased vascularity; malignant cells exhibit elevated VEGF expression promoting neovascularization. PMB can present as frank bloody vaginal discharge, blood-stained vaginal discharge, or excessive spotting; even scant vaginal bleeding in a postmenopausal woman warrants endometrial evaluation. The critical clinical principle is that all postmenopausal bleeding is endometrial cancer until proven otherwise—while many cases will have benign etiologies (atrophy, polyps), presuming benignity without investigation leads to delayed diagnoses. The diagnostic approach begins with clinical evaluation before any assumptions of benignity.

In premenopausal and perimenopausal women, endometrial cancer may present with abnormal uterine bleeding (AUB) characterized by heavy menstrual bleeding (menorrhagia), prolonged menses, or intermenstrual bleeding. These symptoms overlap substantially with benign etiologies (fibroids, polyps, coagulopathy), making diagnosis more challenging in younger women; however, when abnormal bleeding persists despite appropriate medical management or occurs in the context of risk factors (obesity, PCOS, tamoxifen use, Lynch syndrome), endometrial evaluation becomes necessary. Reproductive-aged women presenting with endometrial cancer tend to have more advanced stage disease and poorer outcomes than postmenopausal counterparts, partially because their symptoms are attributed to menstrual dysfunction rather than malignancy.

Vaginal discharge, sometimes described as watery or sanguineous vaginal discharge, occurs in approximately 30% of cases and results from increased endometrial secretion and necrosis of tumor tissue. Discharge may have an offensive odor if associated with tissue necrosis and secondary bacterial colonization. This symptom can prompt patient evaluation and diagnosis but lacks sensitivity for cancer detection.

Pelvic pain or lower abdominal cramping occurs in 10-20% of cases and typically indicates more advanced disease with significant tumor burden, myometrial invasion, or hematometra (blood accumulation within the uterine cavity). Pain results from uterine distension, myometrial invasion, or involvement of pelvic peritoneum and ligaments. The presence of pelvic pain at presentation is an ominous finding associated with higher stage disease and worse prognosis.

In advanced-stage disease, patients may present with constitutional symptoms including unintentional weight loss, fatigue, and malaise resulting from systemic effects of malignancy (TNF-α and IL-6 production, altered metabolism). Abdominal distension and ascites suggest peritoneal involvement or massive ascites formation. Leg edema and thromboembolic events can occur from direct vascular invasion, lymph node obstruction, or malignancy-associated hypercoagulability. Bowel or urinary symptoms (hematuria, rectal bleeding, constipation) indicate direct invasion of bladder or rectum in far-advanced disease.